Reinmuth, N. Et Al. 2022. Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , (ELECTR NETWORK).

Reinmuth, N., Goldman, J. W., Chen, Y., Hotta, K., Statsenko, G., Hochmair, M. J., ... ÖZGÜROĞLU, M.(2022). Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN . Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK

Reinmuth, N. Et Al. "Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN," Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022

Reinmuth, N. Et Al. "Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , ELECTR NETWORK, 2022

Reinmuth, N. Et Al. (2022) . "Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN." Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) , ELECTR NETWORK.

@conferencepaper{conferencepaper, author={N. Reinmuth Et Al. }, title={Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN}, congress name={Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)}, city={}, country={ELECTR NETWORK}, year={2022}}